Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

HIV latency reversal agents: A potential path for functional cure?

Texto completo
Autor(es):
Lopes, Juliana Romano [1, 2] ; Chiba, Diego Eidy [2] ; Dos Santos, Jean Leandro [2]
Número total de Autores: 3
Afiliação do(s) autor(es):
[1] Sao Paulo State Univ UNESP, Inst Chem, Araraquara, SP - Brazil
[2] Sao Paulo State Univ UNESP, Sch Pharmaceut Sci, BR-14800903 Araraquara, SP - Brazil
Número total de Afiliações: 2
Tipo de documento: Artigo de Revisão
Fonte: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY; v. 213, MAR 5 2021.
Citações Web of Science: 0
Resumo

Despite the advances in Human Immunodeficiency Virus (HIV) treatment, the cure for all HIV patients still poses a major challenge, which needs to be surpassed in the coming years. Among the strategies pursuing this aim, the `kick-and-kill' approach, which involves the reactivation and elimination of a latent HIV reservoir that resides in some CD4(+) T cells, appears promising. The first step of this approach requires the use of latency reversal agents (LRAs) that induce the reactivation of the latent virus. Although several classes of LRAs have been reported so far, some limitations of these compounds still need to be overcome before their clinical use. The complete exhaustion of the reservoir of latent virus will contribute to promote the second step of this approach, facilitating the elimination of the reactivated HIV. Therefore, potent, safe, and non-toxic LRAs are necessary to promote efficient elimination of the HIV-1 virus from its reservoir. In this review article, we focus on the promising LRAs that have been described in the literature over the past few years, highlighting the advantages and disadvantages of their use in the `kick and kill' approach, thus opening a new avenue in the development of a potential cure. (C) 2021 Elsevier Masson SAS. All rights reserved. (AU)

Processo FAPESP: 18/11079-0 - Síntese e atividade antituberculose de novos derivados N-óxidos planejados para o tratamento da tuberculose multirresistente
Beneficiário:Jean Leandro dos Santos
Modalidade de apoio: Auxílio à Pesquisa - Regular